Skip to main content

Campbell David Alan's Form 4 filing

Janux Therapeutics, Inc. (JANX) · filed Sep 27, 2024

Accession no.
0001415889-24-024074
Filed
Sep 27, 2024
Trade date
Sep 27, 2024
Filing delay
Same day
Rule 10b5-1 plan
Checked

This filing lists 3 non-derivative transactions. Open-market sales total $1.16M. It was filed on the trade date.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Campbell David AlanCIK 0001864158Director, Officer (President and CEO)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Sep 27, 2024Common StockSSaleDisposed−18,957$46.09F2−$873,728.13313,097Direct
Sep 27, 2024Common StockSSaleDisposed−5,248$46.86F3−$245,921.28307,849Direct
Sep 27, 2024Common StockSSaleDisposed−795$47.84F4−$38,032.8307,054Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F2

The weighted average sale price for the transaction reported was $46.0893 and the range of prices were between $45.55 and $46.54. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

Referenced by the price of 1 transaction in Table I.

F3

The weighted average sale price for the transaction reported was $46.855 and the range of prices were between $46.565 and $47.54. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

Referenced by the price of 1 transaction in Table I.

F4

The weighted average sale price for the transaction reported was $47.8384 and the range of prices were between $47.56 and $48.135. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)